TELA Bio, Inc.

Good day, everyone, and welcome to TELA's first quarter 2026 conference call. At this time, all participants are in a listen-only mode. After the presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1-1 on your telephone. You will then hear a message advising your hand is raised. To withdraw your question, please press star 1-1 again. Please be advised that today's conference is being recorded. I would now like to turn the call over to Louisa Smith. Please go ahead.

Thank you, Carmen, and good afternoon, everyone. Earlier today, Telebio released financial results for the first quarter ended March 31st, 2026. A copy of the press release is available on the company's website. Joining me on today's call are Tony Koblish, Chief Executive Officer, Jeff Blizzard, President, Roberto Cuca, Chief Operating Officer and Chief Financial Officer, and Jim Hagan, SVP of Strategic Operations and Marketing. Before we begin, I'd like to remind you that during this conference call, the company may make projections and forward-looking statements regarding future events. We encourage you to review the company's past and future filings with the SEC, including, without limitation, the company's quarterly reports on Form 10-Q, which identify the specific risk factors that may cause actual results or events to differ materially from those described in these forward-looking statements. These factors may include, without limitation, statements regarding product development, pipeline opportunities, sales and marketing strategies, and the impact of various additional risk factors as identified in our regulatory filings. With that, I'll now turn the call over to Tony.

Thank you, Louisa. Good afternoon, and thank you for joining Telebio's first quarter 2026 earnings call. I'll open with a summary of what we accomplished in the first quarter and our perspective on the road ahead. Jeff will then walk through some updates on progress in the commercial organization and our continued execution against the plan we laid out last quarter. Wilberto will review our financials, and then we will open it up for Q&A. Last quarter, we laid out a framework detailing the decisive steps we have taken to reset our commercial strategy, and Q1 results show early proof points that our strategic plan is working. We currently have the largest, most effective field team in the company's history and have achieved the hiring targets necessary to deliver against our operating plan. Our sales territories are fully staffed with exceptional talent, and new hires are ramping up to productivity levels on expected timelines. The remainder of 26 will be about executing on our redefined strategy and the task ahead is to translate our UCAS commercial reset into measurable success. The foundational work is behind us and we are an inflection point that should become increasingly visible in our results through the remainder of the year. Beyond upgrading our U.S. field team, there are several favorable tailwinds that give me confidence in delivering a strong second half of 2026. To start, On April 1st, we initiated the full U.S. commercial launch of the Ovatex Long-Term Resorbable Reinforcement Portfolio, which we are calling Ovatex LTR. This product is one of the only fully resorbable tissue-based hernia repair solutions on the market. Surgeons and patients are increasingly demanding solutions that deliver durable long-term outcomes while minimizing exposure to permanent synthetic materials. With Ovatex LTR, surgeons now have a full suite of products that offer the critical structure and strength required in the early phases of healing while avoiding the long-term risk of residual plastic material in the body. We believe Ovatex LTR will be instrumental in attracting new surgeons who have yet to adopt Ovatex by offering them and their patients a more effective, fully-resorbable solution. We have priced Ovatex LTR comparably to the rest of our hernia portfolio, preserving the value proposition for both surgeons and hospital administrators. Early feedback in the field has been overwhelmingly positive, and we believe that LTR will be a meaningful contributor to this product portfolio. Second, we saw breakout performance in our European business with revenue growth of 41%. And as a reminder, this growth is driven entirely by our hernia portfolio as we are still in the regulatory process of bringing PRS to the market in Europe. We saw exceptional performance in the UK where we continue to deepen our presence, win new accounts, and gain clinical administrative buy-in driven by our value proposition and product efficacy. As we start to scale within continental Europe, we have found distinct unmet needs in those countries The most pronounced being the demand from government-run healthcare systems seeking novel ways to optimize costs and patient outcomes. TELA is well positioned to win in these market dynamics. A strong validation of TELA's value proposition came through the NHS supply chain's value-based procurement evaluation, which selected Ovitex for use in complex ABWAL procedures. Through independent analysis, the NHS found that Ovitex has the potential to reduce the need for revisional operations for hernia recurrence, lower the prevalence of post-operative complications, improve patient well-being, and generate cost savings compared with other biologic mesh options. We believe these findings are transferable across health systems and see a clear opportunity for our products to perform just as well in additional EU markets. Finally, the quantity and quality of evidence supporting Ovitex continues to grow. Most recently, a meta-analysis was presented at SAGES comparing Ovitex with other mesh options for ventral hernia repair. The authors were highly respected surgeons, well-known thought leaders in the space, and they concluded that Ovitex is a safe and effective option for ventral hernia repair with significantly lower recurrence rates. These data emerged alongside the publication of results from a large real-world European registry evaluating a resorbable competing product which showed recurrence rates exceeding 20%, consistent with several other studies of that product and nearly 10 times the recurrence rates observed across the OVTX portfolio. Before turning it over to Jeff, I'd also like to address the strategic board changes we announced in late April. Four of our long-serving directors, Doug Evans, Kurt Ezerbarzen, Vince Burgess, and Freddie O'Brien, will be stepping down following our annual shareholder meeting on June 9th. We are deeply grateful for their contributions and the strong foundation they helped establish for Telebio. Coming onto the board will be Joe Capper, who is expected to serve as chairman, Guy Nora, Guy O'Neil, and Paul Thomas. Each of them has deep industry experience in scaling med tech companies and navigating strategic transformations. Bill Blavonic and Betty Jo Rocio will stand for reelection at the annual meeting and will provide valuable continuity as we reset our board composition. I am looking forward to working with this new board and believe that it will position TELA to execute with greater speed and focus as we advance our commercial strategy and drive towards sustained profitability. We exit Q1 with a strong foundation from which we can deliver against our commitments in 2026. To summarize, we have a fully staffed US commercial team, an expanded portfolio that includes one of the only fully resorbable tissue-based hernia portfolios on the market, continued evidence supporting the significant benefits of Ovitex, a European business that is driving exceptional performance, and a reconstitutive board of directors to help us achieve our next phase of growth. With that, I'll turn it over to Jeff for a more detailed look at commercial execution. Jeff?